NASDAQ:SKYE - Nasdaq - US83086J2006 - Common Stock - Currency: USD
Overall SKYE gets a fundamental rating of 3 out of 10. We evaluated SKYE against 566 industry peers in the Biotechnology industry. SKYE has a great financial health rating, but its profitability evaluates not so good. SKYE has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -36.51% | ||
ROE | -38.98% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 5.1 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 16.32 | ||
Quick Ratio | 16.32 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:SKYE (5/2/2025, 1:50:21 PM)
2.11
+0.08 (+3.94%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.96 | ||
P/tB | 0.96 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -36.51% | ||
ROE | -38.98% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 537.17% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 16.32 | ||
Quick Ratio | 16.32 | ||
Altman-Z | 5.1 |